Lumos Pharma, Inc.
LUMO · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | -0.59 | -0.01 | 0.46 |
| FCF Yield | -120.05% | -88.14% | -51.38% | -9.51% |
| EV / EBITDA | 0.23 | 0.80 | 1.17 | -5.59 |
| Quality | ||||
| ROIC | -107.05% | -48.49% | -32.02% | -6.16% |
| Gross Margin | 100.00% | 96.78% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.91 | 0.86 | 0.97 | 4.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 107.37% | 108.51% | -37.36% | -48.16% |
| Free Cash Flow Growth | -16.71% | 10.22% | -28.88% | 23.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.94 | 1.74 | 3.03 | 3.82 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 37.37 | -1,995.03 | 203.13 | 57,061.67 |